Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6PE7

Crystal Structure of ABBV-323 FAB

6PE7 の概要
エントリーDOI10.2210/pdb6pe7/pdb
分子名称FAB Heavy Chain, FAB Light chain, SULFATE ION, ... (4 entities in total)
機能のキーワードcd40, fab, immune system
由来する生物種Homo sapiens (Human)
詳細
タンパク質・核酸の鎖数2
化学式量合計48231.68
構造登録者
Argiriadi, M.A. (登録日: 2019-06-20, 公開日: 2019-08-14, 最終更新日: 2024-10-09)
主引用文献Argiriadi, M.A.,Benatuil, L.,Dubrovska, I.,Egan, D.A.,Gao, L.,Greischar, A.,Hardman, J.,Harlan, J.,Iyer, R.B.,Judge, R.A.,Lake, M.,Perron, D.C.,Sadhukhan, R.,Sielaff, B.,Sousa, S.,Wang, R.,McRae, B.L.
CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches.
BMC Mol Cell Biol, 20:29-29, 2019
Cited by
PubMed Abstract: CD40 is a 48 kDa type I transmembrane protein that is constitutively expressed on hematopoietic cells such as dendritic cells, macrophages, and B cells. Engagement of CD40 by CD40L expressed on T cells results in the production of proinflammatory cytokines, induces T helper cell function, and promotes macrophage activation. The involvement of CD40 in chronic immune activation has resulted in CD40 being proposed as a therapeutic target for a range of chronic inflammatory diseases. CD40 antagonists are currently being explored for the treatment of autoimmune diseases and several anti-CD40 agonist mAbs have entered clinical development for oncological indications.
PubMed: 31382872
DOI: 10.1186/s12860-019-0213-4
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.74 Å)
構造検証レポート
Validation report summary of 6pe7
検証レポート(詳細版)ダウンロードをダウンロード

252091

件を2026-04-15に公開中

PDB statisticsPDBj update infoContact PDBjnumon